Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
27 févr. 2020 07h30 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
21 févr. 2020 16h00 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
20 févr. 2020 16h00 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
19 févr. 2020 16h00 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
05 févr. 2020 08h30 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
12 janv. 2020 14h00 HE
|
Atara Biotherapeutics, Inc.
Key milestones anticipated across Atara’s four strategic priorities in 2020 Continued investment in EBV T-cell platform to develop off-the-shelf, allogeneic CAR T immunotherapies leveraging favorable...
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
09 déc. 2019 10h00 HE
|
Atara Biotherapeutics, Inc.
61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study Tab-cel® was generally...
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
26 nov. 2019 16h00 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
07 nov. 2019 07h30 HE
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel...
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
06 nov. 2019 09h01 HE
|
Atara Biotherapeutics, Inc.
26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing...